HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates GRI Bio (NASDAQ:GRI) with a Buy and maintains $10 price target.
Stocks · News reference
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy
https://www.zacks.com/stock/news/2989341/gri-bio-inc-gri-upgraded-to-buy-what-does-it-mean-for-the-stock
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
GRI Bio shares are trading lower after the company announced new translational biomarker data from the Phase 2a GRI-0621-IPF-02 study evaluating GRI-0621 in patients with idiopathic pulmonary fibrosis.
GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study